the world's headlines, one feed
Silence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial. Silence said its drug divesiran met the primary endpoint in ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
This is a major milestone in the Fund's efforts to build strategic partnerships that enhance healthcare delivery
A new study based on data from Estonian residents shows that long COVID and chronic illnesses have a direct two‑way connection.
On Tuesday, August 11, at 12.00, a press conference entitled "Will patients be left without MRI and CT? Threat to diagnostics availability due to new MoH draft law" will start at the press center of…
Mumbai, August 10, 2026: Biodeal Pharmaceuticals on Monday announced a Rs 385 crore investment from RMB Capitalworks for business expansion and research and development activities.
A Wexford GP has been found guilty of professional misconduct over posts on social media during the Covid-19 pandemic which were highly critical of public health measures introduced to tackle the…